



VitamFero wins the 2017 CommBeBiz Innovation award in the agrifood category

This award recognizes the innovation driven by VitamFero's Provicol project and will enable the company to accelerate its European visibility and dynamic commercial development

Angers, France: March 22, 2017

VitamFero, a French veterinary biotechnology company specialized in creating and developing innovative prophylactic solutions, is announcing that it has won the 2017 CommBeBiz Innovation award in the agrifood category for its Provicol project.

This recognition highlights the benefits and relevance of the R&D work carried out by VitamFero, with a number of new proofs of concept expected for 2017. It will also enable VitamFero to further strengthen its visibility in Europe, while the company is gearing up for new industrial partnerships and actively moving forward with the development of its products.

Developed over the past 18 months, the Provicol project is overseeing the creation and development of non-specific immunostimulants offering protection for newborn chicks against infectious diseases. Led by VitamFero, this R&D program is positioned as an alternative to the use of antibiotics for livestock and offers real hope faced with the challenge to provide the protein and food needed by the world's rapidly growing population.

Thanks to this prestigious award, the company will be supported by the CommBeBiz consortium on bioeconomy and entrepreneurial development aspects. Through coaching sessions, meetings with experts, webinars and training sessions, VitamFero will be able to capitalize on a range of innovative tools to accelerate its development.

CommBeBiz is a European project funded by the European Commission's H2020 program. It is led by a consortium of four partners: Minerva Communications (UK), EBN (Belgium), Pracsis (Belgium) and Teagasc (Ireland). Through its members' knowledge and expertise, this consortium is the driving force behind a platform where researchers and startups specialized in the bioeconomy (agriculture, agrifood, biotechnology, marine and forestry) can receive personalized support from renowned industry experts.

Pascal Breton, VitamFero's President and Managing Director: *"We are particularly pleased to have received this award, which recognizes our research and development efforts, and will enable us to promote Provicol, a very important project for our business. By providing innovative solutions to prevent infections affecting newborn chicks, we are actively helping reduce antibiotic use in livestock, a major public health challenge. Alongside this, while the company is embarking on a new phase in its growth, this award will enable us to benefit from extensive support and tools to accelerate our development and ramp up our visibility, while we are starting to put in place a new capital increase"*.

About VitamFero

Founded in 2005, VitamFero is capitalizing on a strongly-growing intellectual property portfolio, covering the prophylactic development and use of live attenuated strains with major technological and commercial potential, achieved through genetic engineering with a high entry barrier and derived from the apicomplexan parasites *Toxoplasma gondii* and *Neospora caninum*. Supported initially by Val de France Angels, then by CapDecisif Management and G1J Ile-de-France since 2011, and by GO Capital, Pradeyrol Développement and CAPAGRO since 2014, VitamFero is able to count on a sound, fully-validated technology that will enable it to offer its first vaccines and immunostimulants by 2020. Learn more at www.vitamfero.com.

Contact

Calyptus - Mathieu Calleux - vitamfero@calyptus.net

VitamFero - Pascal Breton, President and Managing Director - p.breton@vitamfero.com - Tel: +33 (0)6 82 65 47 69